Document is current
Any future updates will be listed below
-
Authors
Radvan, Frederik
Hauser, Alexandra
Lin, Li-Yun
Wilmschen-Tober, Sarah
Schaber, Marion
Bermejo-Jambrina, Marta
Agbabiaka, Tariq Oluwakunmi
Peterhoff, David
Riepler, Lydia
Mendrzyk, Nadja
Beierfuß, Anja
Speth, Cornelia
Moog, Christiane https://orcid.org/0000-0002-0916-156X
von Laer, Dorothee
Wagner, Ralf
Kimpel, Janine https://orcid.org/0000-0002-5210-7905
-
Funding
Funding for this research was provided by:
EC | Horizon 2020 Framework Programme (681032 (EHVA, European HIV Vaccine Alliance))
EC | Horizon 2020 Framework Programme (681032 (EHVA, European HIV Vaccine Alliance))
EC | Horizon 2020 Framework Programme (681032 (EHVA, European HIV Vaccine Alliance))
EC | Horizon 2020 Framework Programme (681032 (EHVA, European HIV Vaccine Alliance))
Bundesministerium für Bildung und Forschung (Project HIVacToGC, Grant 16GW0363K)
- License Information
-
More Information
Article History
Received: 15 August 2024
Accepted: 20 November 2025
First Online: 15 December 2025
Competing interests
: D.v.L. and J.K. are inventors on patents related to VSV-based oncolytic viruses. All other authors declare no conflicts of interest.
